{
    "nct_id": "NCT03291951",
    "official_title": "FOcus on Reducing Dose-limiting Toxicities in Colon Cancer With Resistance Exercise Study",
    "inclusion_criteria": "* Men and women â‰¥18 years\n* Newly diagnosed with histologically confirmed stage II-Ill colon cancer\n* Completed curative-intent surgical resection\n* Currently prescribed one of the following adjuvant chemotherapy regimens: (IV 5-fluorouracil [5-FU] / leucovorin [LV], capecitabine, FOLFOX [5-FU, LV, oxaliplatin], CAPOX [capecitabine and oxaliplatin]\n* Patients must have started chemotherapy or plan to start with receipt of the first exercise visit by 3rd infusion visit. Patients enrolled at the Dana-Farber Cancer Institute and who are receiving FOLFOX chemotherapy are eligible to enroll in the pharmacokinetics sub-study.\n* No planned major surgery anticipated in the intervention period\n* Sufficient time to heal from any major surgery to start of intervention, including colostomy reversal (port-a-cath removal excluded)\n* Approval by either oncologist or surgeon to participate in trial\n* Readiness as determined by the Physical Activity Readiness Questionnaire\n* Ability to understand and the willingness to sign a written informed consent document in English\n* Willingness to be randomized\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Concurrent actively treated other cancer (except non-melanoma skin cancer, in situ cervical cancer or localized prostate cancer treated with surveillance only)\n* Patients with untreated hypertension (>180 mm Hg systolic or >100 mm Hg diastolic) appearing in the patient's medical record in the two weeks prior to screening\n* Presence of metastatic disease\n* Current strength training >2x week for the past 3 or more months\n* Patients enrolled in other clinical trials of weight loss, physical activity or dietary interventions are ineligible.",
    "miscellaneous_criteria": ""
}